May 2004 Table of Contents

External Link - article-94607.pdf

Articles in this issue

about 22 years ago

Article

The Risk Management Mandate

about 22 years ago

Article

Partners in Learning

about 22 years ago

Article

Early Warnings

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Where the True Bottlenecks Exist at FDA for Clinical Trials

ByMike Hollan,Dr. Richard Graham

July 27th 2026

Why GLP-1 Coverage is Important for Menopause

ByMike Hollan,Susan Thomas

July 27th 2026

Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr

ByMike Hollan,Dr. Jan Stoehr

July 27th 2026

Mike Faddoul, Partner, Audit & Assurance, Crowe

Why Gross-to-Net Internal Controls Should Be a Launch Priority for Specialty Pharma Companies

ByMike Faddoul

July 27th 2026

Pharmaceutical Executive Daily: FDA Votes to Reduce Restrictions on Four Peptides

ByNicholas Jacobus

July 24th 2026

May 2004 Table of Contents

Articles in this issue

Related Content

Where the True Bottlenecks Exist at FDA for Clinical Trials

Why GLP-1 Coverage is Important for Menopause

Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr

Why Gross-to-Net Internal Controls Should Be a Launch Priority for Specialty Pharma Companies

Pharmaceutical Executive Daily: FDA Votes to Reduce Restrictions on Four Peptides

Trending on PharmExec

FDA Pannel Votes to Loosen Restrictions for Four Peptides

Pharmaceutical Executive Daily: FDA Votes to Reduce Restrictions on Four Peptides

President Trump Announces Phased Generic Drug Tariff Plan: Report

Retatrutide Delivers Up to 22.6% Weight Loss in Two New Phase III Trials

Where the True Bottlenecks Exist at FDA for Clinical Trials